Edwards Lifesciences Corp. ( (EW) ) has released its Q4 earnings. Here is a breakdown of the information Edwards Lifesciences Corp. presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Edwards Lifesciences Corp. is a leading global company specializing in the innovation of structural heart disease treatments, primarily focusing on technologies for transcatheter heart valve replacement and repair.
Edwards Lifesciences reported strong financial results for the fourth quarter and full year of 2024, with a 9% increase in sales to $1.39 billion, surpassing expectations. The company highlighted significant growth across all product lines, particularly in transcatheter mitral and tricuspid therapies (TMTT), which saw an 88% increase in sales.
Key financial performance metrics include a 6% growth in Transcatheter Aortic Valve Replacement (TAVR) sales, totaling $1.04 billion for the quarter, and a notable 78% increase in full-year TMTT sales. Additionally, the company presented results from two impactful FDA clinical trials, EARLY TAVR and TRISCEND II, which are expected to contribute to future growth.
Edwards also maintained a robust adjusted EPS of $0.59 for the quarter, driven by strong sales performance, and reiterated its guidance for 2025, projecting constant currency sales growth of 8% to 10% and adjusted EPS of $2.40 to $2.50.
Looking forward, Edwards Lifesciences is optimistic about its strategic initiatives and market-leading products, anticipating continued growth and expansion in structural heart therapies and innovations, further enhancing patient care globally.
